Abstract

Objective: This study was designed to investigate the therapeutic efficacy and underlying mechanisms of Gandou Decoction (GDD) in copper-laden hepatolenticular degeneration (HLD) model rats. Methods: In this study, high-performance liquid chromatography (HPLC) fingerprint analysis and eight representative active components were simultaneously measured for quality control of GDD. The therapeutic effect of GDD in HLD was studied by constructing a rat model of copper-laden HLD. The copper levels in the liver, serum, urine, and feces were quantified by atomic absorption spectrophotometry (AAS). Subsequently, UV-Vis spectrophotometry was used to study the coordination ability of copper ion (Cu2+) with six representative active components in GDD to explore its potential copper expulsion mechanism. Serological indexes including alanine aminotransferase (ALT), aspartate aminotransferase (AST), and alkaline phosphatase (AKP) were evaluated. Hepatic indicators including superoxide dismutase (SOD), glutathione (GSH), and the total antioxidant capacity (T-AOC) were determined. Moreover, the liver tissue was stained with hematoxylin-eosin to observe the histological changes. Results: Thirty characteristic fingerprint peaks were used to assess the similarities among 10 samples and showed the similarity was >0.98, indicating a good correlation among the common peaks. Simultaneous quantification of eight markers in GDD was then performed to determine the consistency of quality. GDD could decrease the serum and hepatic copper levels by increasing the urinary and fecal copper content in copper-laden rats. Meanwhile, the results of UV-Vis absorption studies show that six representative active ingredients in GDD can coordinate with Cu2+, indicating that complexing copper removal may be a potential mechanism for GDD to play a role in copper removal. Serum hepatic enzyme markers AST, ALT, and AKP activities and antioxidant enzyme SOD, T-AOC activities, and GSH level in hepatic tissue showed the protection of GDD against liver injury induced by excessive copper. Additionally, the hepatoprotective effect of GDD was also evidenced by the results of the liver histological evaluation. Conclusions: This study suggested that GDD could reduce the serum and hepatic copper levels through promoting urinary and fecal copper excretion in copper-laden rats. At the same time, GDD could alleviate hepatic injury by inhibition of oxidative stress.

Highlights

  • Hepatolenticular degeneration (HLD), known as Wilson’s disease (WD), was first described by Kinnear Wilson in 1912 (Wilson, 1912)

  • 3D-HPLC chromatogram of Gandou Decoction (GDD) was assayed according to the method described previously

  • The results of this study suggest that GDD may cooperate with Cu2+ and excrete from urine and feces to play a role in copper elimination to treat HLD

Read more

Summary

Introduction

Hepatolenticular degeneration (HLD), known as Wilson’s disease (WD), was first described by Kinnear Wilson in 1912 (Wilson, 1912). In the process of hepatolenticular degeneration, defects in the excretory pathway of the liver and impediments to the excretion of copper into bile lead to copper accumulate in the liver and other tissues, which in turn causes extensive damage to organs (Brewer and YuzbasiyanGurkan, 1992). The increasing copper content in the liver accelerates the rate of physiological free radical reactions and further leading to oxidative stress (Musacco-Sebio et al, 2014). Sustained oxidative stress in liver cells accelerates apoptosis and necrosis by destroying lipids, proteins, and DNA (Yang et al, 2016). These modifications eventually result in liver dysfunction (Cichoz-Lach and Michalak, 2014)

Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call